Top in rheumatology: Tavneos vs. prednisone, biology of MIS-C
In a randomized, double-blind, controlled study, Tavneos showed a significantly greater increase in glomerular filtration rate compared with prednisone in patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis.
A report on the data was the top story in rheumatology last week.
Source: Adobe Stock
Another top story was a recap of a presentation at ACR Convergence about the biology of multisystem inflammatory syndrome in children (MIS-C). Researchers characterized MIS-C as having clinical and proteomic heterogeneity, as well as an “outsized” CXCL9 response to interferon-gamma.
Read these and more top stories in rheumatology below:
Tavneos bests prednisone for kidney function recovery in ANCA vasculitis
Tavneos (avacopan, ChemoCentryx) yielded significantly better kidney function outcomes than prednisone in a cohort of patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis, according to data presented at ACR Convergence 2021. Read more.
MIS-C displays clinical, proteomic heterogeneity, 'outsized' CXCL9 levels
MIS-C demonstrates clinical and proteomic heterogeneity, with signals suggestive of thrombotic microangiopathy and macrophage activation syndrome, according to data presented at ACR Convergence 2021. Read more.
Lyme arthritis: A small piece of the larger autoimmunity puzzle
Spotting and managing early Lyme disease can be easy: Just look for the bullseye. But when the rash goes away and the infection remains untreated for a prolonged period, Lyme arthritis can develop. That is when the real challenges begin. Read more.
TULIP: Anifrolumab superior to standard of care for lupus regardless of prior biologic use
A 300-mg dose of Saphnelo (anifrolumab, AstraZeneca) provided clinically meaningful benefit and was generally well-tolerated among patients with systemic lupus erythematosus, regardless of previous exposure to biologic agents, according to data presented at ACR Convergence 2021. Read more.
More than half of patients with rheumatic disease, COVID-19 report 'long-haul' symptoms
COVID-19 symptoms persisted for at least 1 month in nearly 56% of patients with rheumatic disease who contracted COVID-19, according to survey data presented at ACR Convergence 2021. Read more.